| Active substance | durvalumab |
| Holder | AstraZeneca AB |
| Status | closed |
| Indication | First-line Treatment for Patients with Locally Advanced or Metastatic Biliary Tract Cancers in combination with Gemcitabine Plus Cisplatin Therapies |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 03/02/2023 |